SEPN Stock Q2 2026: Septerna Earnings - The Market Paid 23 pct For A Half-Life

Septerna (SEPN) Q2 2026 — The 8-K cleared EDGAR at 4:03pm ET on August 10, AFTER the close, so Tuesday August 11 was the reaction session: the shares opened only +1.85 pct at USD39.57, traded as low as USD38.62, then were bought all day to close +22.93 pct at USD47.76 on 2.91x average volume. USD44.50 on August 14. Septerna is a clinical-stage biotechnology company developing oral small molecule drugs against G protein-coupled receptors, listed on the Nasdaq in October 2024. The June quarter beat on both lines: revenue USD26.7M against a USD19.2M bar, loss per share USD0.29 against USD0.426. But 54.6 pct of that revenue is amortisation of a Novo Nordisk upfront paid in July 2025, 41.9 pct is fully reimbursed research services, and only 3.4 pct is newly earned. THE CALL: AVOID (3/5, MEDIUM - THE MARKET PAID 23 PCT FOR A PHARMACOKINETIC PARAMETER) — base-case value ~$31.92 vs ~$44.50 today. KEY METRICS: - CALL: AVOID, 3/5. Fair value USD31.92 vs the USD44.50 close, -28.3 pct. Bear USD20.89 / base USD29.46 / bull USD42.31, weighted 50/25/25 across ONE model in which only the SEP-479 probability of success moves: 20 pct ours, 13 pct the industry base rate, 50 pct Stifel's own published figure. - THE PRINT: revenue USD26.7M vs USD19.2M expected, a 39.1 pct beat. Loss per share USD0.29 against a USD0.426 bar. R&D USD35.1M vs USD22.2M, G&A USD8.5M vs USD6.9M, operating loss USD16.8M. Net loss USD13.0M against USD24.8M a year earlier, helped by USD4.8M of interest income. - THE EPS BASIS, PROVEN: Q1 USD0.19 loss plus Q2 USD0.29 equals the filed six-month USD0.48 exactly, so the vendor epsActual series is GAAP. Basic and diluted are identical - 6,071,300 dilutive securities were anti-dilutive. FMP did NOT double-count the collaboration revenue. - THE REVENUE IS A SCHEDULE: Note 3 splits the USD26.7M three ways. USD14.6M is amortisation of Novo Nordisk's USD195.0M upfront, USD11.2M is research services Novo reimburses at 100 pct, USD0.9M is milestones. Only 3.4 pct is newly earned. USD140.4M of deferred revenue remains. - WHAT ACTUALLY MOVED IT: the observed elimination half-life of SEP-479 is approximately three to four days, which the company says supports once-daily oral dosing. The same release extended MAD dosing to 14 days and pushed Phase 1 SAD/MAD data to Q1 2027. SEP-631's planned Phase 2b in urticaria was dropped. - CASH IS NOT THE ISSUE: USD516.5M of cash, equivalents and marketable securities at June 30, plus USD33.7M net from the July ATM. Operating outflow USD22.2M in the quarter and USD47.8M in the half. No financial debt - the USD22.5M a screener shows is an operating lease. Runway guided at least into 2029. - THE STREET: 5 dated targets, all bullish, averaging USD50.60 (USD43-USD60). H.C. Wainwright USD60 Aug 12, Guggenheim USD51 Aug 11, Wells Fargo USD50 Aug 12, Stifel USD49 Aug 11, Truist USD43 Jul 1. We sit 36.9 pct below. The tape requires a 55.1 pct probability of success - above Stifel's 50 pct. What to watch: UP: a clean fourteen-day multiple-ascending-dose readout in Q1 2027 showing calcium control with no bilirubin signal, which lifts our 20 pct probability of success materially - every ten points is USD4.28 a share. Also a named, dated trial for SEP-631 in a mast-cell indication. DOWN: any unconjugated bilirubin signal in the extended cohorts, the event that ended SEP-786 on February 18 2025, which takes the model to USD20.89. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.